ACRO Biomedical Co

ACRO Biomedical Co FCF/Net Income

The Free Cash Flow to Net Income Ratio of ACRO Biomedical Co (ACBM) as of Nov 11, 2026 is 194.08 %. In the previous year, Free Cash Flow to Net Income Ratio was 86.75 % — a change of 123.73% (higher).

FCF/Net Income

194.08 %

YoY

123.73%

Last updated:

Free Cash Flow to Net Income Ratio of ACRO Biomedical Co is 2025 194.08 % . Free Cash Flow to Net Income Ratio of ACRO Biomedical Co was 2024 86.75 % . It decreases by 123.73% higher compared to the previous year.

The ACRO Biomedical Co FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
-33.46 USD
Jan 1, 2019
16.07 USD
Jan 1, 2020
169.82 USD
Jan 1, 2021
-3.89 USD
Jan 1, 2022
0.93 USD
Jan 1, 2023
0.93 USD
Jan 1, 2024
86.75 USD
Jan 1, 2025
194.08 USD
The ACRO Biomedical Co FCF/Net Income history
YEARFCF/Net IncomeYoY
194.08 %+123.73%
86.75 %+9,235.54%
0.93 %+0.00%
0.93 %-123.91%
-3.89 %-102.29%
169.82 %+956.90%
16.07 %-148.02%
-33.46 %-100.16%
20,611.39 %+25,664.53%
80.00 %-22.23%
102.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co Ltd is a leading company in biomedical technology based in Taipei, Taiwan. The company was established in 2006 and has since successfully established itself in the global market for biomedical products and technologies. The company's vision is to improve people's lives and promote health worldwide through innovative and high-quality products and solutions. Business model: ACRO Biomedical Co Ltd specializes in the development, manufacturing, and marketing of biomedical products and technologies. The company has three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology. Each division focuses on developing products and solutions tailored to the needs of patients and medical professionals. Regenerative Medicine: ACRO Biomedical Co Ltd is a leading provider of regenerative biomedical products. Under this division, the company develops innovative solutions for tissue regeneration, such as bioimplants made from natural tissues and biomaterials to repair or restore damaged tissue. These products are used for the treatment of injuries, chronic diseases, and degenerative conditions. Additionally, ACRO Biomedical Co Ltd has also developed solutions for cosmetic and aesthetic applications. Wound Care: ACRO Biomedical Co Ltd's wound care division specializes in developing products and solutions that help accelerate wound healing, prevent infections, and reduce the risk of complications. The company offers a wide range of products, including antimicrobial and moist wound dressings, which are used for the treatment of acute and chronic wounds such as burns, abrasions, and diabetic foot ulcers. Surgical Technology: ACRO Biomedical Co Ltd's surgical technology division provides healthcare professionals with a wide range of surgical products for various applications, including neurosurgery, plastic surgery, and general surgery. The innovative products offered by ACRO Biomedical Co Ltd for surgical applications include cutting tools, implants, and instruments for minimally invasive procedures. Products: ACRO Biomedical Co Ltd offers a wide range of products for various applications and medical specialties. Some of the company's key products include: - ACL-Bioimplant: A bioimplant for cruciate ligament repair made from human cartilage and biomaterials. - ACRO-CAF: A bone grafting material for bone transplantation. - ACRO-Mixtop: A wound healing agent for the treatment of burns, abrasions, and chronic wounds. - ACRO-OSTEOT: A surgical bone drill for orthopedics and neurosurgery. - ACRO-BioSIS: A tissue adhesive for surgical applications. Summary: ACRO Biomedical Co Ltd is a leading company in biomedical technology that offers innovative solutions for the preservation and restoration of people's health. With its three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology, the company provides a wide range of products and solutions for medical professionals and patients. The company's products are marketed worldwide and are known for their quality, reliability, and effectiveness. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ACRO Biomedical Co stock

Free Cash Flow to Net Income Ratio of ACRO Biomedical Co is 194.08 % in 2025.

Free Cash Flow to Net Income Ratio of ACRO Biomedical Co changed from 86.75 % to 194.08 %, representing a 123.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio ACRO Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's ACRO Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co